For instance, in early-stage non-small-cell lung cancer (NSCLC), statin use was associated with improved recurrence-free survival primarily in overweight and obese patients; in these patients, statin therapy correlated with increased tumor expression of cytotoxic immune markers such as granzymes and interferon-γ (IFN-γ), suggesting augmented antitumor immunity in the setting of obesity [34]. Here, IFNG is linked to obesity due to melanocortin 4 receptor deficiency.